Index RUT
P/E -
EPS (ttm) -4.84
Insider Own 1.51%
Shs Outstand 75.37M
Perf Week 0.58%
Market Cap 1.39B
Forward P/E -
EPS next Y -1.16
Insider Trans -9.27%
Shs Float 75.34M
Perf Month 24.69%
Income -371.91M
PEG -
EPS next Q -0.64
Inst Own 116.50%
Short Float 9.24%
Perf Quarter 85.82%
Sales 177.64M
P/S 7.82
EPS this Y -136.17%
Inst Trans 0.11%
Short Ratio 4.00
Perf Half Y 233.12%
Book/sh 0.20
P/B 91.64
EPS next Y 67.16%
ROA -59.56%
Short Interest 6.96M
Perf Year 158.25%
Cash/sh 4.25
P/C 4.27
EPS next 5Y -
ROE -582.60%
52W Range 5.12 - 19.25
Perf YTD 101.95%
Dividend Est. -
P/FCF -
EPS past 5Y -12.34%
ROI -90.01%
52W High -5.69%
Beta 0.74
Dividend TTM -
Quick Ratio 2.99
Sales past 5Y 3.07%
Gross Margin 70.18%
52W Low 254.59%
ATR (14) 1.09
Dividend Ex-Date -
Current Ratio 3.04
EPS Y/Y TTM -7.37%
Oper. Margin -178.02%
RSI (14) 70.71
Volatility 5.46% 7.40%
Employees 380
Debt/Eq 26.62
Sales Y/Y TTM -21.42%
Profit Margin -209.36%
Recom 1.31
Target Price 23.20
Option/Short Yes / Yes
LT Debt/Eq 26.27
EPS Q/Q 19.37%
Payout -
Rel Volume 0.41
Prev Close 17.97
Sales Surprise 3.53%
EPS Surprise -15.04%
Sales Q/Q -9.35%
Earnings Oct 31 BMO
Avg Volume 1.74M
Price 18.16
SMA20 11.76%
SMA50 37.03%
SMA200 97.19%
Trades
Volume 525,204
Change 1.03%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-21-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$9 → $27
Oct-16-24 Initiated
Scotiabank
Sector Outperform
Sep-09-24 Upgrade
Guggenheim
Neutral → Buy
$25
Mar-27-24 Downgrade
Guggenheim
Buy → Neutral
Dec-05-23 Upgrade
Citigroup
Neutral → Buy
$7 → $10
Nov-20-23 Initiated
Citigroup
Neutral
$7
Sep-22-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$24 → $8
Sep-21-23 Downgrade
William Blair
Outperform → Mkt Perform
Sep-06-23 Resumed
Evercore ISI
Outperform
$30
Jul-21-23 Initiated
JP Morgan
Overweight
$26
Jun-07-23 Resumed
Piper Sandler
Neutral
$22
May-22-23 Initiated
TD Cowen
Outperform
$30
May-05-23 Upgrade
Bryan Garnier
Sell → Neutral
Mar-01-23 Initiated
Guggenheim
Buy
$37
Feb-21-23 Upgrade
Wedbush
Neutral → Outperform
$30
Dec-14-22 Initiated
Stifel
Hold
$22
Dec-05-22 Initiated
Wells Fargo
Overweight
$28
Sep-21-22 Initiated
Bryan Garnier
Sell
$17
Jul-14-22 Resumed
Canaccord Genuity
Buy
$49 → $42
Mar-31-22 Initiated
Piper Sandler
Overweight
$42
Show Previous Ratings
Oct-21-24 04:30PM
Oct-17-24 07:01AM
02:30AM
Oct-14-24 04:30PM
Oct-09-24 03:50PM
08:02AM
Loading…
08:02AM
Sep-26-24 04:01PM
Sep-12-24 05:00PM
Sep-10-24 04:01PM
Sep-06-24 09:20AM
Sep-05-24 05:34PM
Aug-22-24 04:30PM
Aug-06-24 04:30PM
Aug-01-24 04:01PM
Jul-25-24 04:30PM
08:43AM
Loading…
Jul-10-24 08:43AM
Jul-08-24 04:30PM
(GlobeNewswire) +10.52%
+8.83%
Jun-24-24 07:32AM
Jun-11-24 05:00PM
May-15-24 05:00PM
May-09-24 04:30PM
May-08-24 04:30PM
01:22PM
May-07-24 11:29AM
03:07AM
May-06-24 08:59PM
05:30PM
05:10PM
04:01PM
Apr-29-24 04:30PM
07:05AM
Loading…
Apr-24-24 07:05AM
03:00AM
Apr-04-24 04:30PM
Apr-03-24 04:30PM
Mar-13-24 05:00PM
(GlobeNewswire) +5.16%
-7.61%
Mar-11-24 07:05AM
Feb-26-24 04:30PM
Feb-23-24 07:05AM
02:00AM
Feb-16-24 09:52AM
Feb-15-24 04:01PM
Feb-08-24 04:30PM
Feb-01-24 04:30PM
Jan-25-24 04:05PM
Jan-08-24 07:00AM
Jan-02-24 04:30PM
Dec-14-23 07:30AM
Dec-04-23 04:05PM
Nov-21-23 04:30PM
Nov-09-23 06:26PM
Nov-07-23 04:01PM
(GlobeNewswire) +8.13%
-11.84%
Nov-03-23 10:46AM
Oct-24-23 04:30PM
Oct-13-23 04:30PM
Oct-11-23 05:00PM
Sep-26-23 04:30PM
Sep-22-23 09:38AM
Sep-21-23 07:30AM
Sep-11-23 05:00PM
Sep-05-23 08:30AM
08:30AM
Aug-31-23 04:30PM
Aug-24-23 04:30PM
Aug-14-23 05:00PM
Aug-08-23 06:03AM
Aug-03-23 04:01PM
Jul-26-23 12:28PM
Jul-20-23 04:30PM
Jul-17-23 08:00AM
08:00AM
Jul-11-23 05:00PM
Jun-14-23 05:00PM
Jun-08-23 04:30PM
Jun-01-23 04:30PM
May-31-23 07:00AM
May-11-23 05:00PM
May-04-23 04:01PM
May-01-23 04:05PM
Apr-26-23 04:30PM
Apr-13-23 05:00PM
Apr-01-23 04:30AM
Mar-28-23 04:30PM
Mar-23-23 04:30PM
Mar-14-23 05:00PM
04:30PM
Mar-03-23 04:05PM
Feb-28-23 10:36PM
Feb-27-23 04:01PM
Feb-25-23 07:35AM
Feb-23-23 04:01PM
Feb-17-23 06:30PM
(Business Wire) -12.22%
+19.53%
04:04PM
04:04PM
Feb-16-23 04:30PM
Feb-13-23 05:00PM
Feb-08-23 04:30PM
Jan-12-23 07:00PM
Jan-09-23 07:00AM
Jan-03-23 04:30PM
Dec-14-22 05:00PM
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
LYONS GARY A Director Oct 04 '24 Option Exercise 10.48 40,000 419,200 91,000 Oct 04 07:15 PM LYONS GARY A Director Oct 04 '24 Sale 14.73 40,000 589,101 51,000 Oct 04 07:15 PM GARY A LYONS Officer Oct 04 '24 Proposed Sale 13.65 40,000 546,000 Oct 04 04:21 PM Meckler Jeffrey A Director Sep 30 '24 Option Exercise 10.48 40,000 419,200 121,000 Sep 30 08:38 PM Meckler Jeffrey A Director Sep 30 '24 Sale 14.06 40,000 562,324 81,000 Sep 30 08:38 PM JEFFREY MECKLER Director Sep 30 '24 Proposed Sale 14.06 40,000 562,324 Sep 30 04:22 PM Calvin Sandra Officer Sep 11 '24 Proposed Sale 14.80 15,000 222,000 Sep 11 06:29 PM Inrig Jula CHIEF MEDICAL OFFICER Sep 10 '24 Sale 12.98 684 8,878 61,949 Sep 10 04:05 PM ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Sep 09 '24 Sale 11.52 4,387 50,538 84,455 Sep 09 09:20 PM REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Sep 09 '24 Sale 11.52 4,387 50,538 78,633 Sep 09 09:20 PM Dube Eric M CHIEF EXECUTIVE OFFICER Sep 09 '24 Sale 11.52 21,125 243,360 361,975 Sep 09 09:20 PM Inrig Jula CHIEF MEDICAL OFFICER Sep 09 '24 Sale 11.52 2,191 25,240 62,633 Sep 09 09:20 PM Heerma Peter CHIEF COMMERCIAL OFFICER Sep 09 '24 Sale 11.52 2,191 25,240 107,958 Sep 09 09:20 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Sep 09 '24 Sale 11.52 2,490 28,685 74,595 Sep 09 09:20 PM REED ELIZABETH E Officer Sep 09 '24 Proposed Sale 11.52 4,387 50,538 Sep 09 10:54 AM ROTE WILLIAM E. Officer Sep 09 '24 Proposed Sale 11.52 4,387 50,538 Sep 09 10:35 AM Dube Eric M Officer Sep 09 '24 Proposed Sale 11.52 21,125 243,360 Sep 09 10:34 AM Cline Christopher R. CHIEF FINANCIAL OFFICER Sep 04 '24 Sale 9.51 514 4,888 70,335 Sep 05 09:30 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Apr 11 '24 Sale 6.74 54 364 70,849 Apr 12 04:05 PM Dube Eric M CHIEF EXECUTIVE OFFICER Feb 01 '24 Sale 8.70 19,122 166,435 350,600 Feb 02 04:06 PM ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Feb 01 '24 Sale 8.71 4,764 41,495 80,720 Feb 02 04:05 PM Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Feb 01 '24 Sale 8.53 2,820 24,058 52,017 Feb 02 04:05 PM REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Feb 01 '24 Sale 8.71 4,764 41,495 76,270 Feb 02 04:05 PM Heerma Peter CHIEF COMMERCIAL OFFICER Feb 01 '24 Sale 8.53 4,195 35,789 99,503 Feb 02 04:05 PM Inrig Jula CHIEF MEDICAL OFFICER Feb 01 '24 Sale 8.53 2,174 18,547 58,074 Feb 02 04:05 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Feb 01 '24 Sale 8.53 3,818 32,573 70,903 Feb 02 04:05 PM REED ELIZABETH E SVP, GC & CORPORATE SECRETARY Jan 23 '24 Sale 8.96 2,062 18,476 56,034 Jan 25 04:10 PM Dube Eric M CHIEF EXECUTIVE OFFICER Jan 23 '24 Sale 8.96 7,873 70,542 234,722 Jan 25 04:10 PM Cline Christopher R. CHIEF FINANCIAL OFFICER Jan 23 '24 Sale 9.07 853 7,735 49,721 Jan 25 04:10 PM ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D Jan 23 '24 Sale 8.96 2,062 18,476 60,484 Jan 25 04:10 PM Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Jan 23 '24 Sale 9.07 910 8,252 41,337 Jan 25 04:10 PM Heerma Peter CHIEF COMMERCIAL OFFICER Jan 23 '24 Sale 9.07 1,559 14,138 78,698 Jan 25 04:10 PM Inrig Jula Chief Medical Officer Jan 03 '24 Sale 9.48 2,069 19,613 35,688 Jan 05 04:11 PM Inrig Jula Chief Medical Officer Jan 04 '24 Sale 9.17 440 4,035 35,248 Jan 05 04:11 PM
Index -
P/E 34.69
EPS (ttm) 3.31
Insider Own 2.17%
Shs Outstand 100.98M
Perf Week -2.97%
Market Cap 11.60B
Forward P/E 16.86
EPS next Y 6.81
Insider Trans -7.46%
Shs Float 98.78M
Perf Month -1.42%
Income 339.20M
PEG 0.85
EPS next Q 1.52
Inst Own 93.79%
Short Float 2.48%
Perf Quarter -21.40%
Sales 2.12B
P/S 5.47
EPS this Y 93.40%
Inst Trans 0.53%
Short Ratio 2.65
Perf Half Y -17.37%
Book/sh 24.87
P/B 4.62
EPS next Y 42.58%
ROA 11.46%
Short Interest 2.45M
Perf Year 6.41%
Cash/sh 10.29
P/C 11.16
EPS next 5Y 41.00%
ROE 15.55%
52W Range 103.63 - 157.98
Perf YTD -12.85%
Dividend Est. -
P/FCF 23.44
EPS past 5Y 62.04%
ROI 12.27%
52W High -27.31%
Beta 0.36
Dividend TTM -
Quick Ratio 4.08
Sales past 5Y 34.77%
Gross Margin 97.28%
52W Low 10.81%
ATR (14) 2.43
Dividend Ex-Date Dec 29, 1995
Current Ratio 4.19
EPS Y/Y TTM 87.53%
Oper. Margin 25.70%
RSI (14) 40.20
Volatility 1.63% 1.82%
Employees 1400
Debt/Eq 0.12
Sales Y/Y TTM 26.69%
Profit Margin 16.00%
Recom 1.45
Target Price 164.04
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -34.36%
Payout 0.00%
Rel Volume 0.36
Prev Close 116.78
Sales Surprise 8.10%
EPS Surprise -44.16%
Sales Q/Q 30.37%
Earnings Oct 30 BMO
Avg Volume 926.28K
Price 114.83
SMA20 -0.16%
SMA50 -7.75%
SMA200 -15.05%
Trades
Volume 251,085
Change -1.67%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-10-24 Resumed
Raymond James
Outperform
$155
Aug-29-24 Upgrade
Piper Sandler
Neutral → Overweight
$131 → $159
Apr-24-24 Upgrade
Wells Fargo
Equal Weight → Overweight
$140 → $170
Dec-13-23 Resumed
Citigroup
Neutral
$127
Dec-12-23 Initiated
Deutsche Bank
Buy
$136
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$135 → $140
Aug-21-23 Reiterated
Mizuho
Neutral
$112 → $113
Jul-24-23 Upgrade
SVB Securities
Market Perform → Outperform
$115 → $125
Jul-06-23 Upgrade
BMO Capital Markets
Underperform → Market Perform
$91 → $96
May-04-23 Upgrade
Guggenheim
Neutral → Buy
$145
Mar-30-23 Upgrade
Canaccord Genuity
Hold → Buy
$124 → $132
Mar-03-23 Upgrade
Evercore ISI
In-line → Outperform
$130
Feb-03-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$120 → $130
Nov-14-22 Downgrade
Evercore ISI
Outperform → In-line
$140 → $130
Oct-11-22 Initiated
UBS
Buy
$136
Sep-26-22 Initiated
Wells Fargo
Equal Weight
$110
Jun-06-22 Resumed
Jefferies
Buy
$126 → $112
Mar-03-22 Downgrade
Piper Sandler
Overweight → Neutral
$114 → $94
Feb-25-22 Upgrade
Goldman
Neutral → Buy
$115
Jan-18-22 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$122 → $90
Show Previous Ratings
Today 10:56AM
10:01AM
Oct-17-24 01:02PM
Oct-16-24 04:04PM
Oct-09-24 04:01PM
08:30AM
Loading…
Sep-30-24 08:30AM
Sep-19-24 04:01PM
Sep-14-24 07:25PM
Sep-13-24 04:32AM
Sep-12-24 04:05PM
Sep-10-24 04:01PM
Sep-02-24 10:53AM
(Pharmaceutical Technology)
Aug-30-24 07:41AM
Aug-29-24 01:22PM
06:52AM
06:19PM
Loading…
Aug-28-24 06:19PM
04:28PM
(Investor's Business Daily)
04:05PM
11:16AM
09:56AM
(Investor's Business Daily)
08:17AM
(Investor's Business Daily)
08:15AM
07:07AM
07:00AM
Aug-16-24 07:01PM
Aug-07-24 04:01PM
Aug-06-24 12:45PM
Aug-02-24 06:39AM
01:05AM
Aug-01-24 10:00AM
08:06AM
Loading…
08:06AM
08:05AM
07:09AM
(Associated Press Finance)
07:00AM
Jul-31-24 09:15AM
Jul-25-24 10:02AM
Jul-18-24 08:30AM
Jul-12-24 08:38AM
Jul-11-24 04:01PM
Jul-02-24 06:33AM
(Pharmaceutical Technology)
Jul-01-24 07:30AM
Jun-28-24 04:37PM
Jun-17-24 03:27PM
Jun-14-24 02:34PM
(Investor's Business Daily)
Jun-03-24 08:01AM
07:35AM
07:30AM
May-29-24 04:01PM
May-28-24 04:14PM
08:30AM
May-21-24 04:05PM
May-16-24 04:47PM
May-14-24 08:30AM
May-09-24 11:51AM
(Investor's Business Daily)
11:51AM
(Investor's Business Daily)
09:45AM
08:30AM
02:35AM
May-08-24 08:30AM
May-07-24 04:15PM
08:30AM
May-06-24 08:30AM
May-04-24 08:00AM
(Investor's Business Daily)
May-03-24 01:15PM
May-02-24 11:18AM
03:01AM
01:06AM
May-01-24 11:36PM
(Thomson Reuters StreetEvents)
09:01PM
04:18PM
(Investor's Business Daily)
11:54AM
09:30AM
09:04AM
(Investor's Business Daily)
08:31AM
08:15AM
07:18AM
(Associated Press Finance)
07:00AM
Apr-30-24 05:48PM
05:45PM
05:31PM
05:12PM
09:15AM
Apr-24-24 10:15AM
(Investor's Business Daily)
10:01AM
08:30AM
08:00AM
Apr-23-24 11:50AM
(Investor's Business Daily)
07:22AM
07:00AM
Apr-22-24 11:10AM
Apr-16-24 04:01PM
02:30AM
Apr-10-24 04:01PM
Apr-09-24 07:37AM
Apr-03-24 08:30AM
Mar-28-24 08:30AM
Mar-24-24 09:19AM
Mar-23-24 08:00AM
(Investor's Business Daily)
Mar-16-24 08:00AM
(Investor's Business Daily)
01:23AM
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Boyer David W. Chief Corp. Affairs Officer Sep 13 '24 Sale 121.88 3,461 421,828 1,672 Sep 17 04:21 PM DAVID WARREN BOYER Officer Sep 13 '24 Proposed Sale 121.28 4,756 576,808 Sep 13 04:23 PM RASTETTER WILLIAM H Director Aug 15 '24 Sale 146.69 14,250 2,090,332 37,491 Aug 16 05:00 PM LYONS GARY A Director Aug 13 '24 Option Exercise 42.76 11,570 494,733 130,617 Aug 15 05:21 PM LYONS GARY A Director Aug 13 '24 Sale 150.43 11,570 1,740,450 119,047 Aug 15 05:21 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Option Exercise 73.60 14,100 1,037,760 45,628 Aug 15 05:12 PM ABERNETHY MATT Chief Financial Officer Aug 13 '24 Sale 150.38 14,100 2,120,347 31,528 Aug 15 05:12 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Option Exercise 103.52 3,043 315,011 9,650 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 13 '24 Sale 150.10 7,143 1,072,180 2,507 Aug 15 05:06 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Option Exercise 79.02 273 21,572 6,880 Aug 08 05:16 PM Delaet Ingrid Chief Regulatory Officer Aug 06 '24 Sale 147.70 273 40,322 6,607 Aug 08 05:16 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Option Exercise 61.82 12,632 780,910 30,834 Aug 05 05:40 PM Cooke Julie Chief Human Resources Officer Aug 01 '24 Sale 153.26 12,632 1,936,017 18,202 Aug 05 05:40 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Option Exercise 79.02 2,996 236,744 42,736 Aug 05 05:18 PM Lippoldt Darin Chief Legal Officer Aug 01 '24 Sale 154.01 2,996 461,423 39,740 Aug 05 05:18 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Option Exercise 61.82 900 55,638 19,102 Jul 18 05:12 PM Cooke Julie Chief Human Resources Officer Jul 16 '24 Sale 150.04 900 135,036 18,202 Jul 18 05:12 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Option Exercise 103.52 1,957 202,589 9,064 Jul 18 05:00 PM Delaet Ingrid Chief Regulatory Officer Jul 16 '24 Sale 150.03 2,857 428,627 6,607 Jul 18 05:00 PM LYONS GARY A Director Jul 16 '24 Option Exercise 42.76 930 39,767 119,977 Jul 18 04:54 PM LYONS GARY A Director Jul 16 '24 Sale 150.03 930 139,530 119,047 Jul 18 04:54 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Option Exercise 73.60 900 66,240 32,428 Jul 18 04:45 PM ABERNETHY MATT Chief Financial Officer Jul 16 '24 Sale 150.04 900 135,037 31,528 Jul 18 04:45 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Option Exercise 79.02 7,004 553,456 46,744 Jul 18 04:41 PM Lippoldt Darin Chief Legal Officer Jul 16 '24 Sale 150.00 7,004 1,050,590 39,740 Jul 18 04:41 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Option Exercise 61.82 10,000 618,200 28,202 Jul 02 09:36 PM Cooke Julie Chief Human Resources Officer Jul 01 '24 Sale 140.19 10,000 1,401,864 18,202 Jul 02 09:36 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Option Exercise 79.02 272 21,493 7,779 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer Jul 01 '24 Sale 138.11 272 37,566 7,507 Jul 02 09:09 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Option Exercise 79.02 273 21,572 7,780 Jun 04 04:23 PM Delaet Ingrid Chief Regulatory Officer May 31 '24 Sale 136.55 273 37,278 7,507 Jun 04 04:23 PM SHERWIN STEPHEN A Director May 29 '24 Option Exercise 44.68 40,000 1,787,350 51,504 May 30 04:38 PM SHERWIN STEPHEN A Director May 29 '24 Sale 133.46 40,000 5,338,564 26,504 May 30 04:38 PM Sharp Shalini Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:35 PM Sharp Shalini Director May 17 '24 Sale 141.90 1,106 156,943 994 May 21 05:35 PM POPS RICHARD F Director May 17 '24 Option Exercise 0.00 4,199 0 33,711 May 21 05:27 PM POPS RICHARD F Director May 17 '24 Sale 141.84 2,100 297,860 31,611 May 21 05:27 PM MORROW GEORGE J Director May 17 '24 Option Exercise 0.00 4,199 0 4,199 May 21 05:15 PM Norwalk Leslie V Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 05:06 PM Norwalk Leslie V Director May 17 '24 Sale 141.82 1,106 156,850 994 May 21 05:06 PM LYONS GARY A Director May 17 '24 Option Exercise 0.00 2,100 0 119,047 May 21 04:57 PM SHERWIN STEPHEN A Director May 17 '24 Option Exercise 0.00 4,199 0 26,504 May 21 04:51 PM Mercier Johanna Director May 17 '24 Option Exercise 0.00 2,100 0 2,100 May 21 04:46 PM LYONS GARY A Director May 14 '24 Option Exercise 42.76 12,500 534,500 129,447 May 16 04:55 PM LYONS GARY A Director May 14 '24 Sale 135.63 12,500 1,695,370 116,947 May 16 04:55 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Option Exercise 73.60 15,000 1,104,000 46,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 15 '24 Sale 140.24 15,000 2,103,609 31,528 May 16 04:40 PM ABERNETHY MATT Chief Financial Officer May 14 '24 Sale 135.66 15,000 2,034,826 31,528 May 16 04:40 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Option Exercise 79.02 273 21,572 7,780 May 08 04:26 PM Delaet Ingrid Chief Regulatory Officer May 06 '24 Sale 140.55 273 38,370 7,507 May 08 04:26 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Option Exercise 81.21 19,818 1,609,431 53,365 Apr 17 05:19 PM BENEVICH ERIC Chief Commercial Officer Apr 15 '24 Sale 133.36 19,818 2,643,020 40,778 Apr 17 05:19 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Option Exercise 79.02 272 21,493 7,779 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Apr 01 '24 Sale 137.30 272 37,346 7,507 Apr 03 04:44 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Option Exercise 103.52 5,000 517,600 12,507 Mar 25 06:02 PM Delaet Ingrid Chief Regulatory Officer Mar 21 '24 Sale 145.06 5,000 725,320 7,507 Mar 25 06:02 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Option Exercise 80.90 75,000 6,067,628 110,299 Mar 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Mar 14 '24 Sale 139.38 75,000 10,453,417 40,778 Mar 15 05:33 PM MORROW GEORGE J Director Mar 14 '24 Option Exercise 39.79 40,000 1,591,600 20,000 Mar 15 05:25 PM MORROW GEORGE J Director Mar 14 '24 Sale 139.42 40,000 5,576,710 0 Mar 15 05:25 PM POPS RICHARD F Director Mar 13 '24 Option Exercise 42.76 23,200 992,032 52,712 Mar 15 05:19 PM POPS RICHARD F Director Mar 13 '24 Sale 140.33 23,200 3,255,621 29,512 Mar 15 05:19 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Option Exercise 106.02 3,000 318,060 10,507 Mar 15 05:15 PM Delaet Ingrid Chief Regulatory Officer Mar 13 '24 Sale 140.14 3,000 420,419 7,507 Mar 15 05:15 PM POPS RICHARD F Director Mar 08 '24 Option Exercise 42.76 1,700 72,692 31,212 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Option Exercise 42.76 100 4,276 29,612 Mar 12 06:47 PM POPS RICHARD F Director Mar 08 '24 Sale 140.05 1,700 238,078 29,512 Mar 12 06:47 PM POPS RICHARD F Director Mar 11 '24 Sale 140.00 100 14,000 29,512 Mar 12 06:47 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Option Exercise 106.02 1,800 190,836 9,307 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Option Exercise 106.02 200 21,204 7,707 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 08 '24 Sale 140.03 1,800 252,053 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Mar 11 '24 Sale 140.00 200 28,000 7,507 Mar 12 06:38 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Option Exercise 79.02 6,544 517,107 10,007 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Option Exercise 79.02 273 21,572 7,780 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 28 '24 Sale 135.34 6,544 885,638 7,507 Feb 29 07:02 PM Delaet Ingrid Chief Regulatory Officer Feb 29 '24 Sale 135.51 273 36,994 7,507 Feb 29 07:02 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Option Exercise 53.67 75,000 4,025,043 93,759 Feb 29 06:55 PM BENEVICH ERIC Chief Commercial Officer Feb 28 '24 Sale 134.69 75,000 10,101,608 40,616 Feb 29 06:55 PM Norwalk Leslie V Director Feb 27 '24 Option Exercise 84.95 8,000 679,600 8,000 Feb 29 06:50 PM Norwalk Leslie V Director Feb 27 '24 Sale 135.67 8,000 1,085,388 0 Feb 29 06:50 PM POPS RICHARD F Director Feb 20 '24 Option Exercise 12.98 15,000 194,700 44,512 Feb 22 05:11 PM POPS RICHARD F Director Feb 20 '24 Sale 132.47 15,000 1,987,047 29,512 Feb 22 05:11 PM ROBERTS EIRY Chief Medical Officer Feb 13 '24 Sale 132.96 1,114 148,122 23,716 Feb 15 05:51 PM Onyia Jude Chief Scientific Officer Feb 13 '24 Sale 132.94 1,432 190,371 13,128 Feb 15 05:48 PM Lippoldt Darin Chief Legal Officer Feb 13 '24 Sale 132.99 1,098 146,028 39,740 Feb 15 05:45 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Sale 133.02 2,832 376,700 514,596 Feb 15 05:43 PM Gano Kyle Chief Business Development Off Feb 13 '24 Sale 132.89 1,352 179,674 135,166 Feb 15 05:40 PM Delaet Ingrid Chief Regulatory Officer Feb 13 '24 Sale 133.03 716 95,253 7,507 Feb 15 05:38 PM Cooke Julie Chief Human Resources Officer Feb 13 '24 Sale 133.04 796 105,902 17,976 Feb 15 05:35 PM Boyer David W. Chief Corp. Affairs Officer Feb 13 '24 Sale 133.07 1,811 240,996 4,895 Feb 15 05:33 PM BENEVICH ERIC Chief Commercial Officer Feb 13 '24 Sale 133.01 1,098 146,050 40,616 Feb 15 05:29 PM ABERNETHY MATT Chief Financial Officer Feb 13 '24 Sale 132.85 1,352 179,612 31,528 Feb 15 05:27 PM GORMAN KEVIN CHARLES Chief Executive Officer Feb 13 '24 Option Exercise 39.28 5,090 199,951 512,052 Feb 14 05:17 PM Boyer David W. Chief Corp. Affairs Officer Feb 08 '24 Sale 135.41 1,328 179,830 4,895 Feb 08 07:46 PM Boyer David W. Chief Corp. Affairs Officer Feb 06 '24 Sale 141.96 456 64,734 4,894 Feb 08 07:46 PM Cooke Julie Chief Human Resources Officer Feb 08 '24 Sale 135.44 1,329 179,995 17,263 Feb 08 07:35 PM Cooke Julie Chief Human Resources Officer Feb 06 '24 Sale 142.07 1,215 172,617 17,263 Feb 08 07:35 PM ROBERTS EIRY Chief Medical Officer Feb 06 '24 Sale 142.24 1,121 159,446 21,837 Feb 08 07:28 PM ROBERTS EIRY Chief Medical Officer Feb 08 '24 Sale 134.21 980 131,522 22,717 Feb 08 07:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite